Inclusion Criteria:
* ① Healthy adults aged 20 to 60, regardless of gender;
* Fitzpatrick skin classification II-IV (see Appendix 1 for details); ③ Facial Fitzpatrick wrinkles and elasticity score\>3 points (see Attachment 2 for details); ④ Agree not to take any measures that affect the facial skin condition during the trial period, such as microcrystalline skin rejuvenation, peeling, acne treatment, filler implantation, lifting thread, botulinum toxin treatment, or laser treatment, etc; ⑤ Agree to take and collect facial photos for research purposes and publish them for use in publications; Understand the purpose of this experiment and voluntarily participate in it, sign the informed consent form.
Exclusion Criteria:
* ① Merge severe cardiovascular and cerebrovascular diseases or other systemic diseases.
* Combined with systemic diseases or local skin diseases that may affect wound healing, such as diabetes with poor blood sugar control, immune system diseases, scar constitution, local skin inflammation, skin cancer, etc.
* The treatment area combines the following situations:
1\) Suffering from any skin disease (such as acne, rosacea, eczema, psoriasis, actinic keratosis, severe sun damage, herpes zoster, infection or scarring, etc.); 2) Suffering from active skin inflammation; 3) Abnormal skin sensation; 4) The presence of metal stents or other metal implants; 5) Significant muscle atrophy/excessive weakness; 6) Having perforations or tattoos.
* Within the past 30 days, have received any form of facial skin grinding, chemical peeling, laser freckle removal, or IPL treatment.
* Within the past 90 days, the treatment area has received autologous fat grafting, fractional laser, fillers, botulinum toxin therapy, liposuction, or other types of radiofrequency therapy.
* Within the past 6 months, have received traction therapy;
* There is a history of medication or concomitant medication during the study period, including:
1\) Take nonsteroidal anti-inflammatory drugs such as aspirin, ibuprofen, etc. within 10 days before treatment or within 3 days after treatment; 2) Take acetaminophen within 24 hours before treatment; 3) Antiplatelet therapy should be administered within 72 hours prior to treatment; 4) Perform anticoagulant therapy within 2 weeks before or during treatment; 5) Local steroid therapy within 4 weeks prior to treatment and during the study period, or systemic corticosteroid therapy within 6 months prior to treatment; 6) Administer immunosuppressive drugs within 6 months prior to treatment and during the study period.
⑧ History of allergies to the required materials and ingredients during the treatment process.
⑨ Individuals who are currently participating or have participated in clinical trials of other medical devices or drugs within the past 90 days.
⑩ Pregnant women, lactating women, or those with fertility plans during the trial period.
⑪ Those with severe mental illness who cannot cooperate.
⑫ The researchers believe that participants are not suitable for this experiment.
